cslbehring.comGlobal Biotechnology Company | CSL

Global Selector Newsroom Partnering Contact We Are CSL We Are CSL Our Businesses and Products Vita: Original Stories Our Leadership Worldwide Locations Corporate Governance Our Businesses and Products CSL Behring CSL Seqirus CSL Vifor Corporate Governance Code of Responsible Business Practice Core Policies Vita means life. It’s also our platform for sharing the stories of biotech’s promise to patients and public health. Read the Stories CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section. Our Businesses and Products Patients & Public Health Patients & Public Health Rare & Serious Diseases Iron Deficiency Nephrology Vaccines Patient Support & Organizations Rare & Serious Diseases Immunodeficiency and Autoimmune Diseases Hereditary Bleeding Disorders Hereditary Angioedema Alpha 1 Antitrypsin Deficiency Iron Deficiency Iron Deficiency Patient Stories Nephrology Nephrology Patient Stories Vaccines Pandemic Response In-Licensing Antivenoms and Q fever Vaccine Patient Support & Organizations CSL Behring USA Support & Assistance Programs CSL Vifor Managed Access Programs LEAD Grants Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry. CSL Behring: Rare & Serious Diseases Derived from the expression ’securing health for all of us’, CSL Seqirus is one of the world’s largest influenza vaccine providers. CSL Seqirus: Vaccines R&D R&D R&D Capabilities Awards, Grants and Initiatives World-Class R&D Network Product Pipeline Clinical Studies at CSL Clinical Studies at CSL Current Clinical Trials Research Practices How to Participate Clinical Studies FAQs R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology. R&D Capabilities One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world. Awards, Grants and Initiatives Sustainability Sustainability Environment Social Sustainable Workforce Governance Data and Reporting Centre Environment Climate Resilience Energy and Emissions Waste, Water and Packaging Social Product Safety & Quality Innovation and R&D Access & Health Security Responsible & Resilient Supply Chain Sustainable Workforce Providing A Positive Working Environment Health, Safety & Wellbeing Diversity, Equity & Inclusion Governance Ethics & Transparency Data Protection & Privacy Stakeholder Engagement & Material Topics Data and Reporting Centre Annual Publications Policies Key Performance Data Summary As part of our broader sustainability strategy to build a more sustainable future, we’ve committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030. Learn About Our Targets Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy. Supporting Our Communities Careers Careers Diversity, Equity & Inclusion How CSL Supports Your Well-being Early Careers at CSL Early Careers at CSL Apprenticeships Internships at CSL Graduate Rotational Programs at CSL At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out. Read About Our DE&I Whether you are early in your college education or recently completed your degree, it’s never too soon to consider CSL for your Promising Future! Early Careers at CSL Investors CSL Back Search We Are CSL We Are CSL Our Businesses and Products Our Businesses and Products CSL Behring CSL Seqirus CSL Vifor Vita: Original Stories Our Leadership Worldwide Locations Corporate Governance Corporate Governance Code of Responsible Business Practice Core Policies Patients & Public Health Patients & Public Health Rare & Serious Diseases Rare & Serious Diseases Immunodeficiency and Autoimmune Diseases Hereditary Bleeding Disorders Hereditary Angioedema Alpha 1 Antitrypsin Deficiency Iron Deficiency Iron Deficiency Iron Deficiency Patient Stories Nephrology Nephrology Nephrology Patient Stories Vaccines Vaccines Pandemic Response In-Licensing Antivenoms and Q fever Vaccine Patient Support & Organizations Patient Support & Organizations CSL Behring USA Support & Assistance Programs CSL Vifor Managed Access Programs LEAD Grants R&D R&D R&D Capabilities Awards, Grants and Initiatives World-Class R&D Network Product Pipeline Clinical Studies at CSL Clinical Studies at CSL Current Clinical Trials Research Practices How to Participate Clinical Studies FAQs Sustainability Sustainability Environment Environment Climate Resilience Energy and Emissions Waste, Water and Packaging Social Social Product Safety & Quality Innovation and R&D Access & Health Security Responsible & Resilient Supply Chain Sustainable Workforce Sustainable Workforce Providing A Positive Working Environment Health, Safety & Wellbeing Diversity, Equity & Inclusion Governance Governance Ethics & Transparency Data Protection & Privacy Stakeholder Engagement & Material Topics Data and Reporting Centre Data and Reporting Centre Annual Publications Policies Key Performance Data Summary Careers Careers Diversity, Equity & Inclusion How CSL Supports Your Well-being Early Careers at CSL Early Careers at CSL Apprenticeships Internships at CSL Graduate Rotational Programs at CSL Investors Newsroom Partnering Contact Global Selector ) CSL Behring Pictured: CSL manufacturing employee in Australia CSL We Are CSL Our Businesses and Products CSL Behring Leading the Way on Serious & Rare Diseases CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. Our parent company, CSL, headquartered in Melbourne, Australia, employs more than 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries. CSL Behring Products We develop and deliver innovative medicines for treating bleeding disorders, immune deficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha 1 Antitrypsin Deficiency, among others. See the CSL Behring Global Product List Our Products Achieving better health CSL Behring’s R&D efforts have resulted in a wide range of biotherapy products that have had a lasting impact on human health around the world. Making a difference with one treatment at a time We bring to market biotherapy products for rare diseases that might not have been produced otherwise. Our commitment and delivering our promise We are committed to delivering value through fulfilling unmet needs and enhancing patient experience. Our promise is to protect the health and well-being of people with life-threatening medical conditions. Putting Patients First Our patients are our passion and that drives the way we work. We are committed to full transparency of expectations and outcomes when partnering with them. We listen closely to patients about their experiences and collaborate with them from early research through the delivery of our innovative medicines. Learn More About the Diseases We Treat Vita: You Are Not Alone There is drama and emotion in the promise of biotechnology. We find it in the stories of patients and their families, and in the persistence and resolve of our researchers. And we see it in the drive and enduring optimism of our employees, who are committed to delivering on our promise of a brighter future....